Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. Xellia is a world-leading trusted supplier of several important established anti- infective drugs, comprising active pharmaceutical ingredients as well as finished dosage forms, where the majority are injectable drug products. Headquartered in Copenhagen, and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1700 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.

Our product portfolio of anti-bacterial and investments within inhalable and injectable through managing orders to delivery. anti-fungal products used for the treatment product technologies as we are committed Xellia Pharmaceuticals’ Global Technical of severe infections, including infections to researching solutions, which improve Support team serves as the main point of caused by multi-resistant bacteria and patients’ quality of life. contact for customers to provide them fungi, is the foundation for our growth with specialized support for all technical strategy within the ’ sector. Supplying products to more than 70 matters that may be associated with countries worldwide and with more than market entry and launch of products. Xellia is the leading supplier of important 500 customers internationally, Xellia anti-infectives and colisti- Pharmaceuticals places a high regard Working collaboratively with the sales methate sodium (CMS). Our success and on maintaining strong relationships team and cross-functionally with Xellia’s strong market position is built on more with its customers. internal departments at all sites, Xellia than 115 years’ of pharmaceutical industry Pharmaceuticals is dedicated to providing experience. Our sales team serves as the first point of reliable outstanding service to its contact for customers, ensuring fast and customers at all times. Xellia Pharmaceuticals’ focus its R&D accurate delivery of product information;

INTERNATIONAL SALES OFFICE: Xellia Pharmaceuticals ApS, Copenhagen, Denmark LOCAL SALES OFFICES AND GLOBAL TECHNICAL SUPPORT: A company owned by Novo A/S Tel: +45 32 64 55 00 E-mail: [email protected] www.xellia.com/contact www.xellia.com

Product sheet release date: October 8th, 2019 Active Pharmaceutical Ingredients and Finished Dosage Forms

APIs FDFs

Amphotericin B vials 50.000 units Bacitracin Colistimethate sodium dry-filled vials 1 MIU*, 2 MIU*, 3 MIU* Bacitracin zinc Colistimethate sodium lyophilized vials 150 mg Colistimethate sodium ** vials 350 mg, 500 mg sulfate vials 500.000 units Daptomycin** Vancomycin HCl capsules 125 mg, 250 mg Vancomycin HCl vials 0.5 g, 1 g, 5 g, 10 g Polymyxin B sulfate Voriconazole vials 200 mg sulfate * Million International Units ** Products protected by valid patents are not offered Vancomycin hydrochloride for sale in countries where the sale of such products constitutes a patent infringement

INTERNATIONAL SALES OFFICE: Xellia Pharmaceuticals ApS, Copenhagen, Denmark Tel: +45 32 64 55 00 E-mail: [email protected]

LOCAL SALES OFFICES AND GLOBAL TECHNICAL SUPPORT: www.xellia.com/contact

A company owned by Novo Holdings A/S www.xellia.com